Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 10;65(3):2091-2106.
doi: 10.1021/acs.jmedchem.1c01636. Epub 2022 Jan 22.

Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1 Antagonists

Affiliations

Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1 Antagonists

Cristina Val et al. J Med Chem. .

Abstract

We herein document a large collection of 108 2-amino-4,6-disubstituted-pyrimidine derivatives as potent, structurally simple, and highly selective A1AR ligands. The most attractive ligands were confirmed as antagonists of the canonical cyclic adenosine monophosphate pathway, and some pharmacokinetic parameters were preliminarilly evaluated. The library, built through a reliable and efficient three-component reaction, comprehensively explored the chemical space allowing the identification of the most prominent features of the structure-activity and structure-selectivity relationships around this scaffold. These included the influence on the selectivity profile of the aromatic residues at positions R4 and R6 of the pyrimidine core but most importantly the prominent role to the unprecedented A1AR selectivity profile exerted by the methyl group introduced at the exocyclic amino group. The structure-activity relationship trends on both A1 and A2AARs were conveniently interpreted with rigorous free energy perturbation simulations, which started from the receptor-driven docking model that guided the design of these series.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structure of representative A1 adenosine receptor antagonists.,−
Figure 2
Figure 2
Structure of the model (2- or 4-)-aminopyrimidines (1517) and herein documented A1 antagonists (1820).
Scheme 1
Scheme 1. Three-Component Assembly of the Novel 2-Amino-4,6-diaryl-5-carbonitriles (1820)
Figure 3
Figure 3
Concentration-response curves of the effect of 19ao, 19l, 19v, and XAC on 3 μM forskolin-stimulated cAMP production in the presence of NECA 100 nM.
Figure 4
Figure 4
Affinity-selectivity plot for the 2-amino-4,6-diaryl-5-carbonitriles of series I (18a18 am) and series II (19a19bn). Inverted triangles show dual A2A/A2B compounds.
Figure 5
Figure 5
Affinity-selectivity plot of a selection of 2-amino-4,6-diaryl-5-carbonitriles from series II (the shape indicates the substituent on R2, and the color indicates the substituent on R4).
Figure 6
Figure 6
(A) Two binding modes considered for this series (conformation A, orange; conformation B, magenta) illustrated on compound 19ao on the A1AR (PDB: 5N2S). (B) Scatter plot of the predicted (vertical axis) vs experimental (horizontal axis) binding free energies for the A1AR, as determined by FEP calculations using conformation A. The dots are colored according to the SEM of the associated FEP simulations after cycle closure correction (see Experimental Section).
Figure 7
Figure 7
Binding mode to the A1AR (A–C, PDB: 5N2S) and the A2AAR (D, PDB: 4EIY with closed conformation, red; D–F, PDB: 3UZC, open conformation, gray) of N-substituted compounds: 19l, R2 = Me, orange (A, D); 19m, R2 = Et, green (B, E); 19n, R2 = Ph, blue (C, F).

References

    1. Fredholm B. B.; Ijzerman A. P.; Jacobson K. A.; Linden J.; Müller C. E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update. Pharmacol. Rev. 2011, 63, 1–34. 10.1124/pr.110.003285. - DOI - PMC - PubMed
    1. Jacobson K. A.; Tosh D. K.; Jain S.; Gao Z. G. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front. Cell. Neurosci. 2019, 13, 124.10.3389/fncel.2019.00124. - DOI - PMC - PubMed
    1. Wilson C. N.; S. Jamal M.. Adenosine Receptors in Health and Disease, 1st ed.; Springer: Dordrecht, 2009.
    1. Rivera-Oliver M.; Díaz-Ríos M. Using Caffeine and Other Adenosine Receptor Antagonists and Agonists as Therapeutic Tools against Neurodegenerative Diseases: A Review. Life Sci. 2014, 101, 1–9. 10.1016/j.lfs.2014.01.083. - DOI - PMC - PubMed
    1. Di Angelantonio S.; Bertollini C.; Piccinin S.; Rosito M.; Trettel F.; Pagani F.; Limatola C.; Ragozzino D. Basal Adenosine Modulates the Functional Properties of AMPA Receptors in Mouse Hippocampal Neurons through the Activation of A1R A2AR and A3R. Front. Cell. Neurosci. 2015, 409.10.3389/fncel.2015.00409. - DOI - PMC - PubMed

Publication types

MeSH terms